Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $19.33.

A number of equities analysts recently issued reports on VYGR shares. StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 9th. HC Wainwright started coverage on Voyager Therapeutics in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price target for the company. Guggenheim assumed coverage on shares of Voyager Therapeutics in a research note on Tuesday, March 26th. They set a “buy” rating and a $22.00 price objective on the stock. Finally, Citigroup assumed coverage on shares of Voyager Therapeutics in a research note on Thursday, March 7th. They set a “buy” rating and a $16.00 target price on the stock.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $8.81 on Monday. Voyager Therapeutics has a one year low of $6.06 and a one year high of $14.34. The company has a 50-day simple moving average of $8.85 and a 200-day simple moving average of $7.99. The firm has a market capitalization of $479.18 million, a P/E ratio of 2.85 and a beta of 0.98.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Wednesday, February 28th. The company reported $1.25 EPS for the quarter, topping the consensus estimate of ($0.59) by $1.84. The firm had revenue of $90.06 million during the quarter, compared to analysts’ expectations of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a return on equity of 63.89%. As a group, sell-side analysts forecast that Voyager Therapeutics will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Voyager Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of VYGR. Gladius Capital Management LP acquired a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $25,000. AJOVista LLC acquired a new stake in Voyager Therapeutics during the 4th quarter valued at $39,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Voyager Therapeutics in the fourth quarter valued at $43,000. Tower Research Capital LLC TRC boosted its position in shares of Voyager Therapeutics by 302.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,399 shares of the company’s stock worth $54,000 after buying an additional 4,809 shares during the period. Finally, Aigen Investment Management LP purchased a new position in shares of Voyager Therapeutics during the third quarter valued at $109,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.